CEDRA Clinical Research LLC
San Antonio, Texas, 78217, United States
NCT Number: NCT01010152
The objective of this study was to assess the comparative bioavailability of codeine from Roxane Laboratories' Codeine Sulfate 30mg tablets to Tylenol® #3 (acetaminophen 300mg with codeine phosphate 30mg) under fasted conditions
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
San Antonio, Texas, 78217, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
30 mg Tablet
Other names: Tylenol #3 Tablets
Time frame: 15 days
Roxane Laboratories
Industry
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Comparative Bioavailability Study fo Codeine 30 mg Tablets and Tylenol #3 Tablets Under Fasting Conditions
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02313571
Neurologic Manifestations, Pain
Singapore
View Trial DetailsNCT02373696
Neurologic Manifestations, Pain
Singapore
View Trial DetailsNCT06498713
Agnosia, Nervous System Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT07662564
Dialysis, Neurologic Manifestations
Fatih, İ̇stanbul, Turkey (Türkiye)
View Trial Details